PMID: 31733944
Title: Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes Key considerations from World Health Organization consultations
Abstract: Treating tuberculosis (TB) requires a multidrug course of treatment lasting 6 months, or longer for drug-resistant TB, which is difficult to complete and often not well tolerated. Treatment failure and recurrence after end-of-treatment can have devastating consequences, including progressive debilitation, death, the transmission of Mycobacterium tuberculosis - the infectious agent responsible for causing TB - to others, and may be associated with the development of drug-resistant TB. The burden on health systems is important, with severe economic consequences. Vaccines have the potential to serve as immunotherapeutic adjuncts to antibiotic treatment regimens for TB. A therapeutic vaccine for TB patients, administered towards completion of a prescribed course of drug therapy or at certain time(s) during treatment, could improve outcomes through immune-mediated control and even clearance of bacteria, potentially prevent re-infection, and provide an opportunity to shorten and simplify drug treatment regimens. The preferred product characteristics (PPC) for therapeutic TB vaccines described in this document are intended to provide guidance to scientists, funding agencies, public and private sector organizations developing such vaccine candidates. This document presents potential clinical end-points for evidence generation and discusses key considerations about potential clinical development strategies.
Date: 1970-08-22
Year: 2019
Journal: Vaccine
PMID Author: Vekemans J, Brennan MJ, Hatherill M, Schrager L, Fritzell B, Rutkowski K, De Vos B, Zignol M, Thiry G, Ginsberg AM, Walker B
IAVI Topics: Tuberculosis

Media Contacts


Ethel Makila
+254 71 904 3142 



Hester Kuipers
+31 20 521 0343 



Devi Leena Bose
+91 11 4737 6031 


North America

Rose Catlos
+1 212 847 1049